55 results on '"Huvila, Jutta"'
Search Results
2. Abstract PR002: Proteomic profiling of endometrial carcinomas
3. Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics
4. Endometrial Pipelle biopsy computer-aided diagnosis (ENDO-AID): a feasibility study
5. Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype
6. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids
7. Corrigendum to “Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death”: [Modern Pathology 36 (2023) 100085]
8. Classification of Vulvar Squamous Cell Carcinoma and Precursor Lesions by p16 and p53 Immunohistochemistry: Considerations, Caveats, and an Algorithmic Approach
9. Abstract 6417: Deciphering aberrant STING pathway and exploring oncolytic viruses therapy in low grade serous ovarian carcinoma
10. Abstract 5779: A platform utilizing high-grade serous ovarian cancer organoids for prospective patient stratification in functional precision medicine
11. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death
12. Supplementary figure 1 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
13. Supplementary figure 2 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
14. Supplementary figure 4 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
15. Supplementary figure 3 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
16. Supplementary methods from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
17. Supplementary data from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
18. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer
19. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers
20. The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype
21. Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer
22. EP114/#506 Molecular classification of endometrial carcinosarcoma shows uniformly P53ABN subtype and provide opportunities for diagnostic improvement
23. 37/#877 Hormonal biomarkers remain prognostic relevant within the molecular classification in endometrial cancer
24. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification
25. The proteome of clear cell ovarian carcinoma
26. Significance of p53 and presence of differentiated vulvar intra-epithelial neoplasia (dVIN) at resection margin in early stage human papillomavirus-independent vulvar squamous cell carcinoma
27. Molecular subtype stratified response to adjuvant therapy in endometrial cancer (086)
28. Endometrial Carcinoma Molecular Subtype Correlates With the Presence of Lymph Node Metastases
29. Molecular subclassification of vulvar squamous cell carcinoma: reproducibility and prognostic significance of a novel surgical technique
30. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification
31. Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases
32. A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids
33. Combined expression of HOXA11 and CD10 identifies endometriosis versus normal tissue and tumors
34. An Immune Score Reflecting Pro-and Anti-Tumoral Balance of Tumor Microenvironment Has Major Prognostic Impact and Predicts Immunotherapy Response in Solid Cancers
35. STING pathway expression in low‐grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
36. Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier
37. The ratio of cytotoxic lymphocytes to M2-like macrophages is prognostic in immunogenic tumors
38. The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types
39. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
40. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification
41. Online Training and Self-assessment in the Histopathologic Classification of Endocervical Adenocarcinoma and Diagnosis of Pattern of Invasion: Evaluation of Participant Performance
42. Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis
43. Abstract PR002: Global proteomic profiling of endometrial carcinomas identify prognostic markers
44. The Ratio of Cytotoxic Lymphocytes to M2-Like Macrophages is Prognostic in Immunogenic Tumors and Predicts Immunotherapy Response
45. p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns
46. Stroma Amount in Human Cancer
47. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
48. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma
49. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study
50. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.